Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.38 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.36 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22122577 | 0.85 | SMN1; SMN2 (0.45) | LMNASMN1; SMN2DNM1MAPTCNR1 | |
| SCHEMBL22152236 | 0.81 | CNR2 (0.44) | SMN1; SMN2ABCC2DNM1MAPTCNR1 | |
| SCHEMBL22122374 | 0.79 | LMNA (0.58) | LMNASMN1; SMN2CYP19A1CNR1CNR2 | |
| SCHEMBL22122231 | 0.75 | SMN1; SMN2 (0.39) | SMN1; SMN2DNM1MAPTSCN9AGAA | |
| SCHEMBL24144136 | 0.75 | CYP19A1 (0.44) | LMNASMN1; SMN2CYP19A1HTR6CNR1 | |
| SCHEMBL13152593 | 0.73 | LMNA (0.50) | LMNASMN1; SMN2CYP19A1CYP2C19ABCC2 | |
| SCHEMBL19626268 | 0.73 | LMNA (0.50) | LMNASMN1; SMN2CYP19A1CYP2C19ABCC2 | |
| SCHEMBL31323947 | 0.70 | LMNA (0.64) | LMNACNR1CNR2 | |
| SCHEMBL25742101 | 0.69 | LMNA (0.56) | LMNASMN1; SMN2CYP19A1CYP2C19CNR1 | |
| SCHEMBL24144137 | 0.69 | NR1D1 (0.46) | SMN1; SMN2HTR6CNR1CNR2TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240139185-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2024-05-02 | — | — | US | disclosed |
| EP-3897644-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | Revolution Medicines, Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| CN-113498342-A | Compounds involved in synergistic binding and uses thereof | 锐新医药公司 | 2021-10-12 | — | — | CN | disclosed |
| US-20200197391-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | Revolution Medicines, Inc. | 2020-06-25 | — | — | US | disclosed |
| WO-2020132597-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | Revolution Medicines, Inc. (US) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240139185-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | KRAS, NRAS, HRAS | LMNA 4074/4885SMN1; SMN2 4348/4885CYP19A1 4163/4885 |
| US-20200197391-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | KRAS, NRAS, HRAS | LMNA 4074/4885SMN1; SMN2 4348/4885CYP19A1 4163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.